Arrowhead Listing Upgraded to NASDAQ Global Select Market
PASADENA, Calif. -- February 21, 2014
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company
developing targeted RNAi therapeutics, today announced that it received notice
that the NASDAQ Listing Qualifications Department has approved an application
to upgrade the listing of the Company’s securities from the NASDAQ Capital
Market to the NASDAQ Global Select Market, effective with the opening of
business on February 21, 2014. The NASDAQ Global Select Market is the segment
for public companies that meet the highest listing standards of NASDAQ, with
requirements that include market value, financial, and liquidity measurements.
The Company’s stock will continue to trade under the ticker symbol “ARWR”
after the upgrade.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing
targeted RNAi therapeutics. The company is leveraging its proprietary drug
delivery technologies to develop targeted drugs based on the RNA interference
mechanism that efficiently silence disease-causing genes. Arrowhead
technologies also enable partners to create peptide-drug conjugates that
specifically home to cell types of interest while sparing off-target tissues.
Arrowhead’s pipeline includes clinical programs in chronic hepatitis B virus
and partner-based programs in obesity and oncology.
For more information please visit http://www.arrowheadresearch.com, or follow
us on Twitter @ArrowRes. To be added to the Company's email list to receive
news directly, please send an email to firstname.lastname@example.org.
Arrowhead Research Corporation
Vince Anzalone, CFA
The Trout Group
Press spacebar to pause and continue. Press esc to stop.